May 8 |
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
|
May 8 |
Innoviva to Participate in the BofA Securities Health Care Conference
|
Apr 24 |
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
|
Apr 22 |
Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
|
Mar 4 |
Armata enters $35M credit agreement with Innoviva
|
Mar 4 |
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
|
Feb 29 |
Innoviva GAAP EPS of $0.76, revenue of $85.84M beats by $10.32M
|
Feb 29 |
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
|
Feb 29 |
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
|
Feb 14 |
Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition
|